Harmon Seth 4

4 · Viridian Therapeutics, Inc.\DE · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F2][F5]
2026-03-03+6,267→ 9,881 total
Tax Payment
Common Stock
[F5]
2026-03-03$29.32/sh−2,091$61,308→ 7,790 total
Award
Stock Option (Right to Buy)
[F1]
2026-03-02+102,850→ 102,850 total
Exercise: $30.25Exp: 2036-03-02→ Common Stock (102,850 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-03-02+20,550→ 20,550 total
→ Common Stock (20,550 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-03-03−6,267→ 18,801 total
→ Common Stock (6,267 underlying)

Footnotes (5)

[F1]The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
[F2]Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
[F3]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F4]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F5]Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

Signature

Jennifer Tousignant, Attorney-in-fact|2026-03-04

Documents

1 file